bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.

bioMérieux and Ipsen announce today that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen.

bioMérieux S.A. (Euronext: BIM) announced today that it has concluded a settlement on several licence agreements with GeneOhm Sciences Canada, a subsidiary of Becton, Dickinson and Company, in the field of Methicillin-resistant Staphylococcus aureus (MRSA) detection. This settlement, whose financial terms are confidential, follows arbitration proceedings that bioMérieux initiated against GeneOhm Sciences Canada in April 2007. Stéphane Bancel, Chief Executive Officer of bioMérieux, stated: “This settlement confirms the relevance of the intellectual property rights held by bioMérieux in this field. bioMérieux intends to play a major role in protecting patients from healthcare-associated infections, among which Methicillin-resistant Staphylococcus aureus (MRSA) are of critical concern for hospital clinicians.”